Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Flower in connection with the acquisition of the energy storage facility Bredhälla from OX2
Mandate

Vinge has advised Flower in connection with the acquisition of the energy storage facility Bredhälla from OX2.

June 11, 2024 M&A Banking and Finance Environmental Law Commercial Agreements Real Estate and Construction FDI

The energy storage facility Bredhälla consists of batteries utilizing lithium-ion technology with a total capacity of 42,5MW /42,5MWh spread across 20 modules, making it the largest battery park in Sweden. Bredhälla will provide ancillary services to Svenska Kraftnät to ensure stability in the electricity grid and participate in wholesale markets by providing energy arbitrage.

The acquisition strengthens Flower’s position as the leading battery optimizer in Sweden.

Vinges team mainly consisted of Peter Sundgren and Gustav Wahlberg (M&A), Albert Wållgren and Jolinn Uhlin (Financing), Johan Cederblad and Lina Österberg (Environment), Jolene Reimersson and Carl Lexenberg (Commercial Agreements), Daniel Prawitz and Clara Klingspor (Construction) as well as Daniel Wendelsson, Felizia Wiker, Dagne Sabockis and Alva Chambert (FDI).

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

 Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026